Caris Life Sciences partners with Roche’s Genentechh for cancer targets

Caris Life Sciences’ (CAI) therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech, a member of the Roche Group (RHHBY). In this collaboration, Caris will work to identify and validate novel oncology targets in solid tumor tissue. Under the terms of the agreement, Caris is eligible to receive upfront and near-term payments of $25M and is also eligible for up to $1.1B of potential research, development, commercial and net sales milestone payments, as well as potential tiered royalties on net sales of collaboration therapies. Caris Discovery scientists use an integrated bioinformatics and wet-lab workflow, which combines interrogation of solid tissue and cell-based systems with multimodal data to validate prioritized targets and help advance the development of next generation therapies.